Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.65 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835796 | 1.00 | PPARA (0.65) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL7354938 | 1.00 | PPARA (0.65) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL2748240 | 1.00 | PPARA (0.65) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL2748833 | 0.96 | PPARA (0.61) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL9153101 | 0.93 | PPARA (0.62) | PPARAPPARGCTSKCTSLCTSB | |
| SCHEMBL28895580 | 0.92 | PPARA (0.58) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL28114399 | 0.92 | PPARA (0.58) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL11414810 | 0.92 | PPARA (0.58) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL23927277 | 0.91 | PPARA (0.73) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL7302339 | 0.90 | PPARA (0.64) | PPARAPPARGCTSKTACR1CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-21 | — | — | US | disclosed |
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3086814-B1 | DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | Bayer Pharma AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20180318437-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-5508272-A | SELECTIVE ACE INHIBITORS, HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0674677-A1 | NEW COLLAGEN DERIVATIVES, PRODUCTION PROCESS AND APPLICATION TO THE PREPARATION OF BIOMATERIALS | FLAMEL TECHNOLOGIES (FR) | 1995-10-04 | — | — | EP | disclosed |
| EP-0629627-A2 | Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| WO-1994013731-A1 | NEW COLLAGEN DERIVATIVES, PRODUCTION PROCESS AND APPLICATION TO THE PREPARATION OF BIOMATERIALS | FLAMEL TECHNOLOGIES (FR) | 1994-06-23 | — | — | WO | disclosed |
| EP-0194443-B1 | NOVEL PEPTIDES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PRODUCTION | TANABE SEIYAKU CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
| US-4711878-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1987-12-08 | — | — | US | disclosed |
| EP-0194443-A2 | Novel peptides, compositions containing them and processes for their production | TANABE SEIYAKU CO., LTD. (JP) | 1986-09-17 | — | — | EP | disclosed |
| EP-0069527-B1 | CYSTINE DERIVATIVES | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-08-21 | — | — | EP | disclosed |
| US-4438133-A | EXPECTORANTS, ANTITUSSIVES | RECORDATI S.A. (CH) | 1984-03-20 | — | — | US | disclosed |
| EP-0069527-A2 | Cystine derivatives | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | KIF23, KIF2C, KIF18A | PPARA 3866/4885PPARG 3850/4885CTSK 1549/4885 |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | PPARA 4083/4885PPARG 4186/4885CTSK 1932/4885 |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | PPARA 4418/4885PPARG 4354/4885CTSK 1920/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | PPARA 4488/4885PPARG 4588/4885CTSK 2951/4885 |
| US-20180318437-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | KIF23, KIF2C, KIF18A | PPARA 3866/4885PPARG 3850/4885CTSK 1549/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | PPARA 4535/4885PPARG 4591/4885CTSK 1510/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | PPARA 4083/4885PPARG 4186/4885CTSK 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.